OpGen (NASDAQ:OPGN) Coverage Initiated by Analysts at StockNews.com

Equities research analysts at StockNews.com initiated coverage on shares of OpGen (NASDAQ:OPGN) in a note issued to investors on Monday. The firm set a “sell” rating on the medical research company’s stock.

OpGen Stock Down 17.1 %

NASDAQ OPGN opened at $1.50 on Monday. OpGen has a 52-week low of $1.40 and a 52-week high of $9.90. The company has a fifty day moving average of $1.82 and a 200-day moving average of $2.42.

OpGen Company Profile

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.